Xenon Pharmaceuticals Inc.’s Post

The UK Biobank is a fantastic resource, carefully designed, with in-depth genetic data and health information on 0.5 million participants and long-term follow-up. Facilitating access to the UK Biobank database to researchers from LMICs will help them: 1. Improve their research capacity. I see more students gaining access to this resource for either training purposes or their degree programs. This will, at least, transform how epidemiology and medical statistics is being taught. 2. Continue contributing to high-quality global health research, tackling some of the most pressing global health challenges. 3. Build international collaborations with researchers from other countries. These benefits would: 1. Bridge the current research gap between high-income countries and LMICs. 2. Facilitate access to global research opportunities. 3. Improve economic benefit via increased ability to compete from research grants.

DONATE TO THE MSA DRUG REPURPOSING EXPLORATORY FUND: www.defeatmsa.org/donate ~ Choose the MSA Drug Repurposing Fund - Thank You for the Donation! #defeatmsa #kickmsa #msawarriors #newdrugs #clinical #msaresearch #clinicalresearch #repurposing #drugs ~ About the Cure Parkinson’s UK iLCT Program, a pioneering drug repurposing program for Parkinson’s - explained by Dr Patrik Brundin: https://lnkd.in/gMW86-7f

Happening Today... (and tomorrow) 📆 #BioTrinity is being held in London 👑 for a two days designed to connect people from early stage and emerging life sciences R&D companies, investors, big pharma, academics, charities, government, and service providers. 🔬 💊 💉 Thermo Fisher Scientific's Clinical Trial Division is being represented by Mike Hawkes ACMA and Dillan Vekaria. If you are attending and you have a question about how ThermoFisher can support your clinical trial be sure to connect with my colleagues. They can answer your questions related to #ComparatorSourcing #ClinicalSupplyOptimisation #ClinicalPackaging #IMPBlinding and #GlobalLogistics #clinicaltrials #drugdevelopment #patientfirst

It is a privilege to serve as an advisor to the Lupus Research Alliance (LRA). We reviewed highly innovative and promising research proposals submitted to LRA's Translational Bridge Award program on Monday, June 10, 2024. These proposals aim to combat lupus and associated diseases, bringing promising drugs and technologies to fruition to help those in need. I look forward to collaborating with the Lupus Research Alliance and the Team again in August 2024. https://lnkd.in/gyzX8bS4 With 25+ years of expertise in drug development, due diligence, commercialization, and fundraising, I provide strategic consulting to advance innovative therapies and drive successful outcomes in the pharmaceutical and biotech sectors. #lupus #biotechnology #fundraising #pharmaceuticals #pharma #healthcare #medicine #innovation #strategy #leadership #business #success #duediligence #innoventyx

For anyone that has suffered from pushing the document and data regulatory boulder uphill, only to have to do it again the next day, same path, same grind, crying out in your head (because to do so at work would get you a visit from HR) "please, God!! There has GOT to be a better way than this!!" What's great about Accumulus Synergy: It's not regulatory operations business as usual. It's a creative, strategic, collaborative solution to the crushing boot of inefficiency in the typical regulatory process. Bravo and best of luck! This is clearly a space where creative innovation is needed.

Moving forward the transformation of the regulatory filing process globally

How can individual countries take action to help rebuild the antimicrobial pipeline, ensure sustainable access to these drugs and help stop the growth of AMR? Our latest policy brief (available in English and Danish) outlines actions that could be taken by Denmark to support innovation and access to antimicrobials through creating pull incentives and demonstrates that these policies would give a strong Return on Investment. Our key messages include: 🔸 Even within Denmark, a small country with a relatively low AMR burden, there are nearly 500 deaths directly attributable to AMR each year and another 2,000 deaths associated with AMR. 🔸Based on our modelling (adapted from the excellent work of the Center for Global Development) we estimate that implementing a pull incentive scheme to incentivise the development of 18 new drugs over 30 years would: 🔹 Save 350 lives over 10 years with an ROI of 3.5:1 and 6,700 lives over 30 years with an ROI of 16.5:1 when considering all drug-pathogen combinations.  🔹 Save 250 lives over 10 years with an ROI of 2.5:1 and 4,800 lives over 30 years with an ROI of 11.8:1 when considering the 6 top pathogens. 🔸Denmark has an opportunity to use the ongoing update to its National Action Plan on AMR to include commitments to pull incentive policies and should consider investigating how a pull incentive scheme could be operated within a Danish context and as part of an EU scheme, ideally leading to a pilot program in the coming years. The time for action to support antimicrobial developers and ensure patients have access to the drugs they need to treat increasingly common drug resistant infections is now and we believe that these actions can play an important role in driving this forward. https://lnkd.in/eUxbpA2U

How can individual countries take action to help rebuild the antimicrobial pipeline, ensure sustainable access to these drugs and help stop the growth of AMR? Our latest policy brief (available in English and Danish) outlines actions that could be taken by Denmark to support innovation and access to antimicrobials through creating pull incentives and demonstrates that these policies would give a strong Return on Investment. Our key messages include: 🔸 Even within Denmark, a small country with a relatively low AMR burden, there are nearly 500 deaths directly attributable to AMR each year and another 2,000 deaths associated with AMR. 🔸Based on our modelling (adapted from the excellent work of the Center for Global Development) we estimate that implementing a pull incentive scheme to incentivise the development of 18 new drugs over 30 years would: 🔹 Save 350 lives over 10 years with an ROI of 3.5:1 and 6,700 lives over 30 years with an ROI of 16.5:1 when considering all drug-pathogen combinations.  🔹 Save 250 lives over 10 years with an ROI of 2.5:1 and 4,800 lives over 30 years with an ROI of 11.8:1 when considering the 6 top pathogens. 🔸Denmark has an opportunity to use the ongoing update to its National Action Plan on AMR to include commitments to pull incentive policies and should consider investigating how a pull incentive scheme could be operated within a Danish context and as part of an EU scheme, ideally leading to a pilot program in the coming years. The time for action to support antimicrobial developers and ensure patients have access to the drugs they need to treat increasingly common drug resistant infections is now and we believe that these actions can play an important role in driving this forward. https://lnkd.in/eUxbpA2U

🌐 #RAREis Global Advocate Grant 2024 🗓 Deadline: May 31, 2024 Amgen’s #RAREis Global Advocate Grant is now accepting applications. This initiative aims to support and empower individuals and communities affected by rare diseases worldwide. To qualify for consideration, an organization must be considered a non-profit organization, focused on supporting the rare disease community outside of Amgen’s disease states, all funds will be used in the year received and no healthcare providers will be receiving benefit from this grant. Past grant awardees are eligible to reapply and receive repeat funding. For more details on how to apply, visit 2024 #RAREis Global Advocate Grant (rareiscommunity.com) #WeareBiotech #CommunitySupport #RareDiseases #GlobalAdvocacy #Empowerment #Grant

Every organ donor becomes a catalyst for change, sparking vital conversations about the significance of this selfless act. By sharing your decision, you become an advocate for hope, breaking down misconceptions and inspiring others to follow suit. The beauty of organ donation lies not just in its immediate impact but also in the lasting legacy it creates. It's a gesture that transcends time, touching countless lives in ways we might never fully grasp. This act of giving echoes in the lives of recipients, their families, and even in the healthcare community that witnesses the miracle of transplantation. This moment, this choice, have the potential to change destinies and rewrite stories. Let's come together to shine a light on the importance of organ donation. Spread awareness, share stories, and celebrate the immeasurable impact of those who have chosen to be lifesavers.  https://lnkd.in/dpSaaZV6 #OrganDonation #LifeSavers #DonateLife #Transplantation #LegacyOfHope #InspireChange #OrganDonor #Neuncopharmaceutical #pharma #Neunco